Breast Cancer: Open Trials

ABCSG 33R

Register for women with lymph node macrometastases where no axillary dissection is performed.


ABCSG 36/Penelope

Phase III trial to evaluate palbociclib (PD-0332991) in patients (HR-positive, HER2 normal) with primary breast cancer, with risk of relapse following neoadjuvant chemotherapy


ABCSG 41/OlympiA

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase-III-study to assess the efficacy and safety of olaparib vs. placebo as adjuvant treatment in patients with germline BRCA1/2-mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.


ABCSG 42/PALLAS

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer


ABCSG 43/INSEMA

Intergroup-Sentinel-Mamma (INSEMA)-Trial: Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial.


ABCSG 46/CompLEEment-1

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.


ABCSG 48/POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy.